RPHM
Income statement / Annual
Last year (2024), Reneo Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Reneo Pharmaceuticals, Inc.'s net income was $0.00.
See Reneo Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$529.00 K
|
$50.00 K
|
$37.00 K
|
$34.00 K
|
| Gross Profit |
$0.00
|
-$525.00 K
|
-$529.00 K
|
-$50.00 K
|
-$37.00 K
|
-$34.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$43.80 M
|
$56.09 M
|
$37.71 M
|
$28.17 M
|
$15.94 M
|
$13.10 M
|
| General & Administrative Expenses |
$10.59 M
|
$25.79 M
|
$16.14 M
|
$11.65 M
|
$3.61 M
|
$2.38 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.59 M
|
$25.79 M
|
$16.14 M
|
$11.65 M
|
$3.61 M
|
$2.38 M
|
| Other Expenses |
$0.00
|
$650.00 K
|
$1.89 M
|
$48.00 K
|
$87.00 K
|
$3.04 M
|
| Operating Expenses |
$54.39 M
|
$83.05 M
|
$53.85 M
|
$39.82 M
|
$19.55 M
|
$15.47 M
|
| Cost And Expenses |
$0.00
|
$83.05 M
|
$53.85 M
|
$39.82 M
|
$19.55 M
|
$15.47 M
|
| Interest Income |
$2.01 M
|
$0.00
|
$1.89 K
|
$48.00
|
$87.00 K
|
$456.00 K
|
| Interest Expense |
-$300.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$170.00 K
|
$529.00 K
|
$50.00 K
|
$37.00 K
|
$34.00 K
|
| EBITDA |
-$54.39 M |
-$82.23 M |
-$53.76 M |
-$39.77 M |
-$19.52 M |
-$15.44 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
$5.67 M
|
$1.89 M
|
$48.00 K
|
$87.00 K
|
$3.04 M
|
| Income Before Tax |
$0.00
|
-$77.39 M
|
-$51.96 M
|
-$39.77 M
|
-$19.47 M
|
-$12.44 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$1.89 M
|
-$186.56 K
|
-$169.30 K
|
-$137.86 K
|
| Net Income |
$0.00
|
-$77.39 M
|
-$50.06 M
|
-$39.77 M
|
-$19.47 M
|
-$12.44 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
0 |
-2.3 |
-2.04 |
-2.19 |
-0.8 |
-1.6 |
| EPS Diluted |
0 |
-2.3 |
-2.04 |
-2.19 |
-0.8 |
-1.6 |
| Weighted Average Shares Out |
$34.47 M
|
$33.61 M
|
$24.50 M
|
$18.14 M
|
$24.21 M
|
$7.79 M
|
| Weighted Average Shares Out Diluted |
$34.47 M
|
$33.61 M
|
$24.50 M
|
$18.14 M
|
$24.21 M
|
$7.79 M
|
| Link |
|
|
|
|
|
|
